Guselkumab (GUS)

DRUG4 trials

Sponsors

Alimentiv Inc., Xian-Janssen Pharmaceutical Ltd., Second Affiliated Hospital, School of Medicine, Zhejiang University, Caja Costarricense de Seguro Social

Conditions

CD - Crohn's DiseaseCrohn DiseaseCrohn's DiseaseIBD - Inflammatory Bowel DiseasePsoriasisPsoriasis (PsO)Psoriasis ArthritisStricture; Bowel

Phase 4

A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)

RecruitingNCT07310095

Xian-Janssen Pharmaceutical Ltd.Crohn Disease

Start: 2025-12-30End: 2027-11-15Target: 78Updated: 2026-08-27

Unknown Phase

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

Active, not recruitingNCT06249555

Alimentiv Inc.Crohn's Disease

Start: 2024-03-20End: 2026-12-01Target: 300Updated: 2026-08-21

Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease

RecruitingNCT07444060

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCD - Crohn's Disease, IBD - Inflammatory Bowel Disease, Stricture; Bowel

Start: 2026-03-01End: 2029-12-31Target: 100Updated: 2026-03-02

Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease

Not yet recruitingNCT07448402

Caja Costarricense de Seguro SocialPsoriasis, Psoriasis Arthritis, Psoriasis (PsO)

Start: 2026-05-01End: 2031-05-01Target: 50Updated: 2026-03-09